Cervical Cancer

Agent induces apoptosis to kill cancerous and precancerous cervical cells

Published in Women's Health Weekly, May 30th, 2002

by Sonia Nichols, senior medical writer - A new agent now being tested in phase II clinical trials of patients with cervical cancer kills not only cancerous cells but also precancerous cells by inducing them to commit programmed cell death, or apoptosis.

The agent, difluoromethylornithine (DFMO), is an antiangiogenic therapy that also inhibits the action of the enzyme ornithine decarboxylase, according to the authors of a multicenter research study. In preliminary trials to establish the drug's safety, it has reduced cervical intraepithelial neoplasia (CIN) 3 lesions by half, the researchers say. The group has now elucidated the way DFMO works by studying immortalized...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-05-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry